
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
On december 1st 2023, Seqens completed the acquisition of CELLforCURE. Originally a versatile CELL&GENE CDMO, CELLforCURE gained thorough experience in commercial CAR-T cells manufacturing. With 2 200m2 GMP production areas, 6 equipped production suites and 180 seasoned highly skilled experts, CELLforCURE offers versatile and flexible capacities. Located in France, 20km away from the Paris Orly Airport, CELLforCURE is an EMA approved production site and is compliant with FDA standards. The site brings analytical, development and regulatory services to serve client needs across the overall product life cycle. CELLforCURE teams aim at partnering with innovators to develop and manufacture CELL&GENE therapies...
Cellforcure by seqens operates in the Biotechnology research industry.
Cellforcure by seqens's revenue is 11m - 100m
Cellforcure by seqens has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.